Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1468-5922.12939 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Survey of Employed Orthopedic Surgeons Ability to Estimate Operating Room Device Costs.
S D Med
December 2024
Sanford Orthopedics and Sports Medicine, Sioux Falls, South Dakota.
Background: Orthopaedic devices represent a large amount of the overall cost incurred in the operating room. It is unknown if employed sports medicine surgeons are aware of the true prices of these devices. The purpose of this study was to assess sports medicine orthopaedic surgeons' knowledge of implant and device costs, as well of commonly used items in their operating rooms.
View Article and Find Full Text PDFCHROMOPHOBE HEPATOCELLULAR CARCINOMA: DIAGNOSTIC CHALLENGES.
Arq Bras Cir Dig
January 2025
Mongi Slim Hospital, Department of Pathology - Marsa, Tuni, Tunísia.
Background: Hepatocellular carcinoma (HCC) encompasses rare variants like chromophobe hepatocellular carcinoma (CHCC) characterized by distinct histological features and molecular profiles.
Case Report: A 56-year-old male with chronic hepatitis C, presenting pain in the right hypochondrium. Imaging revealed a solitary liver lesion, subsequently resected and histologically diagnosed as HCC.
Cannabis oil in treating Parkinson's disease: improvement of motor and non-motor symptoms: a case report.
Braz J Biol
January 2025
Universidade Federal da Paraíba, João Pessoa, PB, Brasil.
Parkinson's disease (PD) is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in the production of dopamine. Medication with levodopa becomes less effective as the disease progresses. Despite the excellent results observed in clinical practice with the medicinal use of Cannabis in the treatment of PD, the level of scientific evidence is still limited due to the small number of studies published in this field.
View Article and Find Full Text PDFPhase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).
Cancer Chemother Pharmacol
January 2025
Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Background: ATR is an apical DDR kinase activated at damaged replication forks. Elimusertib is an oral ATR inhibitor and potentiates irinotecan in human colorectal cancer models.
Methods: To establish dose and tolerability of elimusertib with FOLFIRI, a Bayesian Optimal Interval trial design was pursued.
[CAR-T therapy in elderly patients with relapsed/refractory diffuse large B-cell lymphoma. Clinical case of the San Martino Hospital in Genoa.].
Recenti Prog Med
January 2025
Divisione di Ematologia e terapie cellulari, Irccs Ospedale Policlinico San Martino, Genova.
CAR-T therapy (chimeric antigen receptor T-cell) has revolutionized the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) that have relapsed or are refractory to conventional chemotherapies. In particular, patients who have relapsed or are refractory to two lines of therapy are patients who have a poor prognosis. The advent of CAR-T immunotherapy is an innovative approach with which we can give hope of recovery even in the case of refractory disease, even for patients who are not candidates for high-dose therapies, for example due to age.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!